A Randomised, Double-Blind, Placebo Controlled Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer's Disease.

Trial Profile

A Randomised, Double-Blind, Placebo Controlled Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs PBT 2 (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Therapeutic Use
  • Acronyms IMAGINE
  • Sponsors Prana Biotechnology
  • Most Recent Events

    • 17 Jul 2014 According to the Prana Biotechnology media release, data from this trial was presented at the Alzheimer's Association International Conference 12-14 Jul 2014.
    • 31 Mar 2014 Status changed from active, no longer recruiting to completed, as reported in a Prana Biotechnology media release.
    • 31 Mar 2014 Top-line results reported in a Prana Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top